Free Trial
NASDAQ:ADAP

Adaptimmune Therapeutics Q2 2025 Earnings Report

Adaptimmune Therapeutics logo
$0.15 +0.02 (+18.99%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$0.14 -0.01 (-6.19%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Adaptimmune Therapeutics Revenue Results

Actual Revenue
$13.68 million
Expected Revenue
$11.04 million
Beat/Miss
Beat by +$2.64 million
YoY Revenue Growth
N/A

Adaptimmune Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Adaptimmune Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Adaptimmune Therapeutics Earnings Headlines

Adaptimmune Appoints New CFO Christopher Hill
Why BRICS, BlackRock, and Singapore Are All Aligned
This Crypto Could Thrive as Global Tensions Rise Right as capital begins to rotate back into crypto, my top Fall 2025 pick sits at the center of it all...tc pixel
Adaptimmune Therapeutics (ADAP) Gets a Sell from Barclays
See More Adaptimmune Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adaptimmune Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptimmune Therapeutics and other key companies, straight to your email.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics (NASDAQ:ADAP) is a clinical-stage biotechnology company focused on the development of novel T-cell therapies for the treatment of solid tumors. The company’s proprietary technology platform, known as SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells, uses affinity-enhanced T-cell receptors (TCRs) to target cancer-associated antigens with precision. Adaptimmune’s research and development efforts are centered on engineering patient-derived T cells to recognize and eliminate tumor cells while sparing healthy tissues.

Since its founding in 2008 as a spin-out from Oxford University, Adaptimmune has advanced multiple product candidates into clinical trials. Lead programs include ADP-A2M4, targeting the cancer testis antigen MAGE-A4, and ADP-A2AFP, directed against alpha-fetoprotein in liver cancer. The company also maintains preclinical discovery efforts against other tumor-associated antigens, aiming to expand its pipeline across a range of solid tumor indications such as ovarian, head and neck, and lung cancers.

Adaptimmune operates research and development facilities in Oxford, U.K., and a clinical and manufacturing center in Philadelphia, Pennsylvania. The company conducts multicenter clinical trials primarily in the United States and Europe, collaborating with academic institutions and biopharmaceutical partners to facilitate patient access and advance its programs through late-stage development.

Governed by a management team with deep expertise in oncology and cell therapy, Adaptimmune is led by Chief Executive Officer James Noble, who joined the company in 2021. Adaptimmune Therapeutics is publicly traded on the Nasdaq Global Market under the ticker symbol ADAP and continues to pursue strategic collaborations and potential regulatory filings as it works to bring its engineered T-cell therapies to patients with unmet medical needs.

View Adaptimmune Therapeutics Profile

More Earnings Resources from MarketBeat